PDCD1 and neoplasm: As for patients 1 and 2, the TCR selection for patient 3 was based on TIL-prevalence, high tumor-to-nontumor frequency ratio and high frequency among PD-1-positive TILs (Supplementary Table S4, Figure 1D).